Skip to main content
Clinical Trials/JPRN-jRCTs031230484
JPRN-jRCTs031230484RecruitingPhase 2

The long-term safety and effect of memantine on PTSD: an open trial

Yoshiharu Kim0 sites40 target enrollmentStarted: November 29, 2023Last updated:

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Sponsor
Enrollment
40

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 18age old to < 60age old (—)
Sex
All

Inclusion Criteria

  • 1) PTSD patients who are over 18 years old and under 60 years old.
  • 2) Patients who are receiving outpatient treatment at the National Center of Neurology and Psychiatry Hospital, collaborative research institutions, or other psychiatric medical institutions.
  • 3) Patients who have the capacity to give informed consent themselves and from whom informed consent can be obtained.
  • 4) Patients who wish to participate in this trial after successfully completing the fixed-dose administration and observation period in the exploratory randomized double-blind placebo-controlled comparison trial evaluating the efficacy and safety of memantine for PTSD conducted at our center, with Dr. Kim Yoshiharu as the principal investigator.

Exclusion Criteria

  • 1) Patients with active schizophrenia or significant manic episodes in bipolar disorder.
  • 2) Patients with strong suicidal ideation.
  • 3) Patients with severe physical illnesses that could interfere with participation in the study, such as fractures.
  • 4) Patients who are pregnant.
  • 5) Patients who have the following physical illnesses, which are labeled as cautionary use in the package insert:
  • -Patients with a history of epilepsy or seizures
  • -Patients with impaired renal function
  • -Patients with factors that increase urine pH (renal tubular acidosis, severe urinary tract infection, etc.)
  • -Patients with severe liver dysfunction
  • 6) Any other patients who the attending physician determines are not suitable for inclusion in the study.

Investigators

Sponsor
Yoshiharu Kim

Similar Trials